LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC (http://lundinlawpc.com/) announces that it is investigating claims against TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (Nasdaq: TGTX) concerning possible violations of federal securities laws.
To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at firstname.lastname@example.org.
On October 13, 2016, TG Therapeutics announced that it filed an amended protocol with the U.S. Food and Drug Administration (“FDA”) for its leukemia drug combination, GENUINE Phase 3 Trial. The Company no longer benefits from its previously negotiated Special Protocol Assessment with the FDA. When this information was disclosed to the public, shares of TG Therapeutics fell in value.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.